louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00672503: Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit
Official title: "Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Tract Infections
Keywords: indwelling urinary catheters
urinary tract infections
foley-catheter related infections
hospital acquired CA-UTI
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
First posted: 2008-05-06
Enrollment: 321
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Patients who acquired a CA-UTI while hospitalized in the PICU between 2004-2007.
2. Patients who had an indwelling urinary catheter while hospitalized in the PICU between 2004-2007 but did not acquire a CA-UTI.
3. Nurses currently employed in the PICU at Children's Mercy Hospital.
4. All Patient's who acquired a CA-UTI during 2009

Brief summary: The purpose of this study is to identify risk factors associated with indwelling urinary catheters, as well as to assess the nurses' knowledge and adherence to hospital policies. The study will also include a very extensive literature search in an attempt to create a national standard or guideline.


Eligibility criteria: Inclusion Criteria:

1. Medical records of 67 patients 0 to 17 years of age diagnosed with a catheter associated urinary tract infection (defined by CDC) acquired during a PICU hospitalization.
2. Medical records of 67 patients 0 to 17 years of age who had an indwelling urinary catheter during a PICU hospitalization without a catheter associated urinary tract infection.
3. Nurses employed at Children's Mercy Hospital in the PICU.
4. Patient's who acquired a CA-UTI during 2009 and was adjudicated by infection control.

Exclusion Criteria:

Patients

1. Patients with community acquired urinary tract infections
2. Patients 18 years and older cared for in the PICU.
3. Patients with catheter associated urinary tract infections hospitalized outside the PICU at Children's Mercy Hospital.
4. Patients with UTI not related to catheterization

Nurses

1. Nurses floated to the PICU who are not permanent staff members (ICN nurse, float pool staff, travelers)
2. Nurses on the research team

Primary outcomes:
measure: Identification of risk factors associated with indwelling urinary catheters.
timeFrame: 2004-2007
Secondary outcomes:
measure: Identification of nurses' knowledge of insertion, irrigation, care and maintenance of indwelling urinary catheters.
timeFrame: 2008
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Children's Mercy Hospitals and Clinics
state: Missouri
Study officials:
affiliation: Children's Mercy Hospital Kansas City
name: Tangela M Welch, ADN, BBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03506503: Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia
Official title: Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Androgenic Alopecia
Keywords: nanofat
hair loss
prp
Lead sponsor: Jinan University Guangzhou
Sponsor class: OTHER
First posted: 2018-04-24
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Nowadays, multiple treatment modalities have been applied clinically to treat androgenic alopecia, such as Follicular unit transplantation(FUT), finasteride, platelet-rich plasma injection(PRP), etc. In this clinical trial, the investigators aim to analyze the effect of nanofat grafting on treating androgenic alopecia in male.

Detailed description: The investigators will treat the hair loss area of a patient by processed nanofat grafting. The participants were asked to come back 1、3、6、9、12 months after treatment for further follow-up.

Before and after the treatment, the hair and follicular will be assessed subjectively by satisfaction assessment, dermatoscope.

Eligibility criteria: Inclusion Criteria:

* Male patients with androgenic alopecia aging from 18 to 50.
* No scars and wounds on the alopecia area.
* No skin disease or serious cardiovascular disease.
* Preoperative examinations remain healthy.

Exclusion Criteria:

* Serious chronic heart, liver, kidney, blood system disease
* Allergic diseases, skin inflammation or wounds
* Alopecia but not androgenic alopecia
* Acute or chronic infection
* Take anticoagulant drugs
* Active vitiligo, psoriasis, systemic lupus erythematosus

Primary outcomes:
measure: Dermatoscope
timeFrame: Baseline and at1,3,6,9,12 months after the treatment
Secondary outcomes:
Other outcomes:
measure: Satisfaction assessments
timeFrame: 1,3,6,12 months after treatment
Locations:
city: Guangzhou
country: China
facility: the first affiliated hospital of Jinan University
state: Guangdong
Study officials:
References:
citation: Tonnard P, Verpaele A, Peeters G, Hamdi M, Cornelissen M, Declercq H. Nanofat grafting: basic research and clinical applications. Plast Reconstr Surg. 2013 Oct;132(4):1017-1026. doi: 10.1097/PRS.0b013e31829fe1b0.
citation: Won CH, Park GH, Wu X, Tran TN, Park KY, Park BS, Kim DY, Kwon O, Kim KH. The Basic Mechanism of Hair Growth Stimulation by Adipose-derived Stem Cells and Their Secretory Factors. Curr Stem Cell Res Ther. 2017;12(7):535-543. doi: 10.2174/1574888X12666170829161058.
citation: Gu Z, Li Y, Li H. Use of Condensed Nanofat Combined With Fat Grafts to Treat Atrophic Scars. JAMA Facial Plast Surg. 2018 Mar 1;20(2):128-135. doi: 10.1001/jamafacial.2017.1329.
Clinical trial NCT03929003: Inspired: Smartphone Videogame-Based Smoking Cessation Intervention
Official title: Breathe Free: Smartphone Videogame-Based Incentives for Smoking Cessation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking Cessation
Lead sponsor: Rowan University
Sponsor class: OTHER
First posted: 2019-04-26
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two group randomization
Primary purpose: TREATMENT

Brief summary: The investigators are testing a new, smartphone videogame-based intervention for smoking cessation.

Detailed description: The investigators have developed a novel smartphone videogame, where smokers are required to submit breath carbon monoxide samples to demonstrate smoking abstinence, and where they will earn game-based rewards contingent on meeting CO goals. Players will be working with teams to earn group and social rewards to help advance their game.

Eligibility criteria: Inclusion Criteria:

* Inclusionary criteria: Participants will be required to be of legal smoking age (\>19 in Alabama, Alaska, New Jersey, Utah, and in Onondaga, Nassau and Suffolk Counties in New York, \> 18 years of age in the remainder of the United States). Participants must also report smoking \>10 cigarettes per day, report smoking for \>2 years, answer 8 or higher on a Likert scale asking how much the person wishes to quit smoking right now (1 = not at all, 10 =very much), have a smartphone with a data plan and active contract extending for at least two months from the enrollment date (i.e., the duration of the study), and reside in the U.S. Participants in the study must submit an initial CO reading \> 10ppm (to prevent nonsmokers from enrolling in the study), Literacy will be assessed by having the participant read the first few lines of the consent form out loud, and will be an inclusion criterion because elements of "Breathe Free" will require reading.

Exclusion Criteria:

* Individuals will be excluded from the study if they report smoking any combustible products \>2 times per month, report unstable medical/psychiatric conditions that might interfere with the study objectives (e.g., asthma), report living with someone who smokes in the house, or has a career that results in excessive exposure to CO. All excluded participants will be emailed the following smoking cessation information: the "Clearing the Air" packet developed by the National Cancer Institute, Smokefree.gov, Quitsmokinghelpline.com, and the National Academies Press "Dying to quit."

Primary outcomes:
measure: Smoking abstinence
timeFrame: 7 days
Secondary outcomes:
measure: Demographic
timeFrame: 7 weeks
Other outcomes:
Locations:
city: Glassboro
country: United States
facility: Rowan University
state: New Jersey
Study officials:
References:
citation: Upton CR, Nastasi JA, Raiff BR. Identifying Video Game Preferences Among Adults Interested in Quitting Smoking Cigarettes: Survey Study. JMIR Serious Games. 2022 Mar 24;10(1):e30949. doi: 10.2196/30949.
Clinical trial NCT04036903: D-Lung: An Analytics Platform for Lung Cancer Based on Deep Learning Technology
Official title: D-Lung: An Analytics Platform for Primary Lung Cancer Screening, Diagnosis and Management Based on Deep Learning Technology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Keywords: Lung nodules
Deep learning
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Department of Computer Science & Engineering, CUHK
First posted: 2019-07-30
Enrollment: 130
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This is a single institutional retrospective cohort study of patients within hospitals in Hong Kong, who had undergone thoracic CT for suspicious lung nodules.

Brief summary: Lung cancer is one of main cause of cancer death in worldwide, characterized of low 5-year survival rate of less than 20%. Pulmonary nodule is considered as the typical imaging manifestation in early stage of lung cancer. The National Lung Screen Trial has demonstrated that the mortality rates could decline greatly, by the utility of low-dose helical computed tomography for screen of pulmonary nodules. Thus, automatic detection, diagnosis and management of pulmonary nodules, play the vital roles in computer-aided lung cancer screening and early intervention.


Eligibility criteria: Inclusion Criteria:

* Subjects with suspicious lung nodules.
* Thin-layer thoracic CT and pathology examination have been performed for suspicious lung nodules.

Exclusion Criteria:

* Subjects with accompanied lesions on CT images that may interfere to lung nodules analysis

Primary outcomes:
measure: accuracy
timeFrame: 2 years
measure: sensitivity
timeFrame: 2 years
measure: specificity
timeFrame: 2 years
measure: area under curve (AUC)
timeFrame: 2 years
Secondary outcomes:
measure: average number of false positives per scan (FPs/scan)
timeFrame: 2 years
measure: competition performance metric (CPM)
timeFrame: 2 years
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The Chinese University of Hong Kong, Prince of Wale Hospital
state: Shatin
Study officials:
References:
Clinical trial NCT03279003: Study of the Efficacy and Tolerance of Light Therapy in Sensitive Skin
Official title: Study of the Efficacy and Tolerance of Light Therapy by Light-emitting Diode (LED) in Sensitive Skin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sensitive Skin
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2017-09-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Light-emitting diode (LED) light therapy is increasingly used successfully and without adverse effects in diabetic leg ulcer, chronic low back pain, chronic myofacial pain in the neck and in several dermatoses such as acne, Psoriasis, alopecia areata and skin rejuvenation. A Korean study conducted in 2013 suggested its effectiveness in patients with sensitive skin in connection with rosacea, acne, eczema. The objective of the study is to perform a study in subjects with a sensitive skin without associated dermatosis.

Detailed description: The objective of the study is to evaluate the efficacy of light-emitting diode therapy in subjects with sensitive skin and to assess pain improvement, evaluation of improvement in pruritus and evaluation of treatment tolerance.

Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years
* Age less than or equal to 70
* Sensitive skin defined by a score ≥ 40 on the Sensiscale scale
* Patient able to consent

Exclusion Criteria:

* Persons under 18 years of age or over.
* Persons suffering from disorders of higher functions preventing comprehension of the questionnaire.
* Pregnancy.
* Analgesic or medication acting on the nervous system.
* Other dermatosis of the face (example: rosacea, seborrheic dermatitis, acne ...).
* Neurological or psychiatric illness.
* A photosensitizing drug.
* Refusal of patient
* Patients under legal protection

Primary outcomes:
measure: Efficacy of light therapy
timeFrame: 2 months
Secondary outcomes:
measure: Assessment of pain improvement
timeFrame: 2 months
measure: Assessment of improvement in pruritus
timeFrame: 2 months
measure: Assessment of the tolerance
timeFrame: 2 months
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
References:
Clinical trial NCT02435303: Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)
Official title: Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Hypertension, Pulmonary
Diseases of Mitral Valve
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2015-05-06
Enrollment: 2
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Sildenafil is effective in the treatment of sustained pulmonary artery hypertension after corrected mitral valve disease.


Eligibility criteria: Inclusion Criteria:

* New York Heart Association Functional class (NYHA Fc) ≥ 2 dyspnea which was sustained till one year after the previous mitral valve surgery (repair or replacement)
* TR Vmax ≥ 3.5m/s by echocardiography
* Normal left ventricle ejection fraction (EF ≥ 50%)
* Pulmonary vascular resistance ≥ 3 Wood Unit or diastolic pressure gradient ≥ 7mmHg by cardiac catheterization

Exclusion Criteria:

* Other valve disease more than moderate degree (ex. aortic stenosis, aortic regurgitation)
* Liver cirrhosis
* Chronic renal failure with serum creatinine ≥ 1.7mg/dL
* Lung disease (ex. chronic obstructive pulmonary disease, Asthma)
* Thyroid dysfunction
* Other causes which can lead to pulmonary hypertension

Primary outcomes:
measure: Change of Six Minutes Walk Distance
timeFrame: baseline and six months
Secondary outcomes:
measure: Borg dyspnea score
timeFrame: six months
measure: Exercise capacity by cardiopulmonary exercise test
timeFrame: six months
measure: Fractional area change of right ventricle measured by echocardiography
timeFrame: six months
measure: Pulmonary vascular resistance (PVR) measured by cardiac catheterization
timeFrame: six months
measure: Systolic pulmonary artery pressure measured by cardiac catheterization
timeFrame: six months
measure: Mean pulmonary artery pressure measured by cardiac catheterization
timeFrame: six months
Other outcomes:
Locations:
Study officials:
affiliation: Asan Medical Center
name: Jong-Min Song
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06691503: A Clinical Trial of Esophagectomy for Esophageal Carcinoma
Official title: A Phase II Clinical Trial of Mediastinoscopic-assisted Transhiatal Laparoscopic Esophagectomy for Early-stage Thoracic Esophageal Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Esophageal Squamous Cell Carcinoma
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2024-11-15
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Single Group:mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE);Thirty-five eligible patients with ESCC were assigned to the MATLE group
Primary purpose: TREATMENT

Brief summary: Brief Summary The pathological type of esophageal cancer (EC) in most patients in East Asia is esophageal squamous cell carcinoma (ESCC). Surgery is the primary treatment for EC. This study compared the feasibility and safety of mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE) with video-assisted thoracoscopic esophagectomy (VATE).

Thirty-five eligible patients with ESCC were assigned to the MATLE group, while seventy matched patients were assigned to the VATE group. The study compared perioperative outcomes and lymph node dissection between the two groups. Additionally, the Kaplan-Meier method was employed to estimate Disease-Free Survival (DFS) and Overall Survival (OS).


Eligibility criteria: Inclusion Criteria:

* previously untreated
* histologically confirmed
* potentially resectable thoracic ESCC clinically staged as T1b-3N0M0 or Tis-1aN0M0 who was not suitable for endoscopic resection according to the 8th edition of the American Joint Committee on Cancer staging system and National Comprehensive Cancer Network Clinical Practice Guidelines in Esophageal and Esophagogastric Junction Cancers
* age 18-70 years,
* normal hematologic and organ function -Karnofsky Performance Scale (KPS) was assessed as 100 or 90

Exclusion Criteria:

* a history of other malignancies
* severe comorbidities
* active autoimmune disease
* prior non-infectious pneumonitis or interstitial lung disease

Primary outcomes:
measure: Disease-Free Survival (DFS) and Overall Survival (OS)
timeFrame: DFS : From date of surgery until the date of first documented progression , assessed up to 100 months; OS :From date of surgery until the date of death, assessed up to 100 months
Secondary outcomes:
Other outcomes:
Locations:
city: GuangZhou
country: China
facility: 651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China
state: Guangdong
Study officials:
References:
Clinical trial NCT06889103: Turkish Edinburgh Feeding Evaluation in Dementia (EdFed) Scale
Official title: Psychometric Properties of the Turkish Version of the Edinburgh Feeding Evaluation in Dementia (EdFed) Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dementia
Feeding Difficulties
Reliability and Validity
Keywords: dementia
EdFed
interobserver agreement
Lead sponsor: Istanbul University - Cerrahpasa
Sponsor class: OTHER
First posted: 2025-03-21
Enrollment: 55
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Nursing home

Brief summary: This study was conducted to evaluate the psychometric properties, including interobserver agreement, of the Turkish version of the Edinburgh Feeding Evaluation in Dementia (EdFed) scale, which was developed to assess eating difficulties in patients with dementia.

Detailed description: Eating difficulties are common in dementia patients and can lead to malnutrition. Early detection and intervention of these difficulties is of great importance to minimise the negative effects. Therefore, a reliable and valid tool for assessing nutritional difficulties in dementia patients is needed.

Eligibility criteria: Inclusion Criteria:

* Those over the age of 65,
* Those diagnosed with dementia,
* Patients who are able to weigh themselves (no lower extremity loss)

Exclusion Criteria:

• (CDR\<2)

Primary outcomes:
measure: Edfed score
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Darülaceze
state: Sıslı
Study officials:
affiliation: ÜSKÜDAR ÜNİVERSİTESİ
name: Büşra Kul, MsC
role: PRINCIPAL_INVESTIGATOR
affiliation: İstanbul University-Cerrahpaşa
name: Zelıha Tulek, Proffessor
role: STUDY_DIRECTOR
References:
citation: Bagnasco A, Watson R, Zanini M, Rosa F, Rocco G, Sasso L. Preliminary testing using Mokken scaling of an Italian translation of the Edinburgh Feeding Evaluation in Dementia (EdFED-I) scale. Appl Nurs Res. 2015 Nov;28(4):391-6. doi: 10.1016/j.apnr.2015.02.003. Epub 2015 Feb 26.
Clinical trial NCT05291403: Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion
Official title: The Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined With Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion: a Multicenter, Prospective, Randomized, Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Non Small Cell Lung Cancer
Keywords: advanced Non-small Cell Lung Cancer
Malignant Pleural Effusion
Thoracoscopy
Cryotherapy Effect
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2022-03-22
Enrollment: 141
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study intends to investigate the efficacy and safety of medical thoracoscopic cryotherapy combined with standard first-line treatment of advanced non-small cell lung cancer with malignant pleural effusion through a randomized controlled clinical trial.


Eligibility criteria: Inclusion Criteria:

1. 18-75 years old;
2. Non-small cell lung cancer with pleural metastasis confirmed by histopathology or cytology;
3. ECOG score 0-1;
4. Cardiopulmonary function can tolerate painless thoracoscopic examination;
5. Patients who underwent medical thoracoscopy for pleural effusion at first diagnosis and underwent medical thoracoscopy cryotherapy at the same time of biopsy were also included in the study. Non-small cell lung cancer was confirmed by pathological results;
6. All subjects or their guardians must sign the informed consent before entering the study.

Exclusion Criteria:

1. Expected survival \<2 months;
2. Hemoglobin \<110g/L, white blood cell count \<3×109/L, neutrophil \<2.0×109/L, platelet \<100×109/L;
3. severe cardiac insufficiency, abnormal liver and kidney function (blood test results of transaminase and creatinine \> 1.5 times the normal upper limit);
4. have received chemotherapy or anti-angiogenic drugs (such as bevacizumab, endu, anlotinib, etc.);
5. History of radiotherapy;
6. history of intrathoracic local treatment;
7. multiple serous cavity effusion, or bilateral pleural effusion;
8. patients allergic to erythromycin;
9. the lung cannot be reopened.

Primary outcomes:
measure: pleural progression free survival, P-PFS
timeFrame: up to 2 months
Secondary outcomes:
measure: Total effective rate
timeFrame: up tp 2 months
measure: Progression-free survival (PFS)
timeFrame: up to 2 months
measure: modified Medical Research Council Dyspnea Scale
timeFrame: up to 2 months
measure: Overall survival time
timeFrame: up to 2 months
measure: Adverse reactions
timeFrame: up to 2 months
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University
state: Shandong
Study officials:
References: